Eyenovia Q1 net loss $5.7M; FDA approves Mydcombi for mydriasis

HYPERION DEFI, INC.

2023-Q1 EPS reported -$0.15

FDA approved Mydcombi (tropicamide/phenylephrine) for mydriasis, first product using Optejet delivery system.
Received FDA feedback on Microline presbyopia candidate providing clear and efficient path forward.
Entered co-development agreement with Formosa Pharmaceuticals to combine Optejet with APNT nanoparticle platform.
Q1 net loss $5.7M ($0.15/share) vs $7.3M ($0.24/share) in Q1 2022; operating expenses down to $5.5M.
Cash and equivalents $18.5M at March 31, 2023; additional $5M available on Avenue Capital credit facility.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HYPERION DEFI, INC. reported first quarter ended March 31, 2023 results: net income $(5.7) million, EPS $(0.15) per share.

Period: first quarter ended March 31, 2023
Net income: $(5.7) million
EPS: $(0.15) per share
Result: reported results

Exact text from the filing

For the first quarter of 2023, net loss was approximately $(5.7) million, or $(0.15) per share

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-059164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.